[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Li et al., 2021 - Google Patents

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Li et al., 2021

View HTML @Full View
Document ID
5049270105284397670
Author
Li K
Shi H
Zhang B
Ou X
Ma Q
Chen Y
Shu P
Li D
Wang Y
Publication year
Publication venue
Signal transduction and targeted therapy

External Links

Snippet

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Li et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Wu et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wang et al. Role of tumor microenvironment in cancer progression and therapeutic strategy
Chen et al. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Marzagalli et al. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Yang et al. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation
Murciano-Goroff et al. The future of cancer immunotherapy: microenvironment-targeting combinations
Ni et al. The role of tumor-stroma interactions in drug resistance within tumor microenvironment
Kodumudi et al. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma
Parker et al. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment
Solito et al. Myeloid‐derived suppressor cell heterogeneity in human cancers
Muller et al. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Kurt et al. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Hargadon Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
Molinier‐Frenkel et al. Immunosuppressive enzymes in the tumor microenvironment
Guo et al. Translation of cancer immunotherapy from the bench to the bedside
Zhao et al. Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Shi et al. Myeloid-derived suppressor cells: implications in the resistance of malignant tumors to T cell-based immunotherapy
Group Young Researchers in Inflammatory Carcinogenesis et al. The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer
Park et al. Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies
US20200323905A1 (en) Methods and compositions for modulating the immune system
Lu et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Zhang et al. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy
Zhang et al. Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy
Wong et al. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far